IP Library Granted Patent US 9,556,455
Granted Patent B2
US 9,556,455 · App. 14/473,868 · Granted Jan 31, 2017

Mature dendritic cell compositions and methods for culturing same

Inventors: Don Healey (Rougemont, NC); Irina Tcherepanova (Rougemont, NC); Melissa Adams (Chapel Hill, NC)
Assignee: Argos Therapeutics, Inc.
C12N15/87C12N5/0639A61K2039/5154C12N2500/36C12N2501/02C12N2501/22C12N2501/23C12N2501/24C12N2501/52C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,556,455
App. No.
14/473,868
Granted
Jan 31, 2017
Kind
B2
Abstract

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-γR) agonist and/or a tumor necrosis factor alpha receptor (TNF-αR) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7 + mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g., mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface.

Claims (27)

1. A method for preparing CD83 + CCR7 + mature dendritic cells mDCs), comprising the sequential steps of:

(a) culturing isolated immature dendritic cells (iDCs) in culture medium comprising an interferon gamma receptor (IFN-γR) agonist and a TNF-αR agonist to produce CD83 + mDCs; and

(b) cotransfecting said CD83 + mDCs with mRNA encoding CD40L polypeptide and mRNA encoding an antigen approximately 12 to 30 hours after initiating step (a) to produce CD83 + CCR7 + mDCs; wherein the CD40L polypeptide comprises amino acid residues:

(i) 51 through 261 of SEQ ID NO: 2, or

(ii) 120 through 261 of SEQ ID NO: 2.

2. The method of claim 1 , wherein said culture medium further comprises PGE 2 .

3. The method of claim 1 , wherein said CD83 + mDCs are cotransfected using electroporation.

4. The method of claim 1 , wherein said iDCs are generated by contacting isolated human monocytes with GM-CSF and at least one of IL-4 or IL-13.

5. The method of claim 1 , wherein said iDCs are prepared from CD34 + hematopoietic stem or progenitor cells.

6. The method of claim 1 , wherein said IFN-γR agonist is IFN-γ.

7. The method of claim 1 , wherein said TNF-αR agonist is TNF-α.

8. The method of claim 1 , wherein said culturing is in the absence of an effective amount of IL-1β and IL-6.

9. The method of claim 6 , wherein said IFN-γ comprises a polypeptide having at least 95% sequence identity with SEQ ID NO:6.

10. The method of claim 6 , wherein said IFN-γ comprises the sequence of SEQ ID NO:6.

11. The method of claim 1 , wherein said mRNA encoding said CD40L polypeptide is in vitro translated mRNA.

12. The method of claim 1 , wherein said mRNA encoding an antigen is in vitro translated mRNA.

13. The method of claim 1 , wherein said mRNA encoding said CD40L polypeptide and the mRNA encoding said antigen are in vitro translated mRNAs.

14. A method for preparing CD83 + CCR7 + mature dendritic cells (mDCs), comprising the sequential steps of:

(a) culturing isolated immature dendritic cells (iDCs) in culture medium comprising an interferon gamma receptor (IFN-γR) agonist and a TNF-αR agonist to produce CD83 + mDCs; and

(b) cotransfecting said CD83 + mDCs with mRNA encoding a CD40L polypeptide and mRNA encoding an antigen approximately 12 to 30 after initiating step (a) to produce CD83 + CCR7 + mDCs, wherein said mRNA encoding said CD40L polypeptide comprises:

(i) a polynucleotide comprising nucleotides 190 to 822 of SEQ ID NO:1, or

(ii) a polynucleotide comprising nucleotides 397 to 822 of SEQ ID NO:1.

15. The method of claim 1 , further comprising cryopreserving said cotransfected CD83 + CCR7 + mDCs.

16. The method of claim 15 , wherein said CD83 + CCR7 + mDCs are cryopreserved 4 hours post cotransfection.

17. The method of claim 1 , wherein said isolated iDCs are cultured for approximately 12 to 30 hours.

18. The method of claim 1 , wherein said mRNA encodes CD40L polypeptide consisting of amino acid residues 51 through 261 of SEQ ID NO: 2.

19. The method of claim 1 , wherein said mRNA encodes CD40L polypeptide consisting of amino acid residues 120 through 261 of SEQ ID NO: 2.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: ARGOS THERAPEUTICS, INC.
To: COIMMUNE, INC.
Reel/Frame 048645/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2014
From: HEALEY, DON; TCHEREPANOVA, IRINA; ADAMS, MELISSA; HINOHARA, ATSUSHI
To: ARGOS THERAPEUTICS, INC.; KIRIN BEER KABUSHIKI KAISHA
Reel/Frame 033827/0750 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2014
From: KIRIN HOLDINGS KABUSHIKI KAISHA
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 033827/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2014
From: KYOWA HAKKO KIRIN CO., LTD.
To: ARGOS THERAPEUTICS, INC.
Reel/Frame 033828/0022 →
CHANGE OF NAME Recorded Sep 26, 2014
From: KIRIN BEER KABUSHIKI KAISHA
To: KIRIN HOLDINGS KABUSHIKI KAISHA
Reel/Frame 033831/0951 →
Continuity (3)
Continuation 11246387 · Oct 7, 2005
Provisional Application 60522512 · Oct 7, 2004
Related Publication 20150072431A1 · Mar 12, 2015